Urinary Tract Stones Risk Factors in Patients with Benign Prostatic Hyperplasia in West Java, Indonesia

Iman Surendroputro Tjahjodjati, Bambang Sasongko Noegroho, Aaron Tigor Sihombing


Background: Urinary tract stones are common in patients with benign prostatic hyperplasia (BPH); therefore, an imaging test is needed for patients who have risk factors for the formation of urinary tract stones. The purpose of this study was to explore the factors associated with the presence of urinary tract stones in patients with BPH as information to conduct imaging tests.

Methods: A cross-sectional quantitative analytic study was conducted on medical records of patients with BPH, both with and without urinary tract stones, or patients with urinary tract stones registered at the Department of Urology, Dr. Hasan Sadikin General Hospital, Indonesia, from 2015 to 2018. Data on age, body mass index, hypertension, use of antihypertensive drugs, diabetes mellitus, and hyperuricemia were collected and analyzed using the Mann-Whitney, Chi-square, Fisher exact test, and multivariate logistic regression statistical test to compare variables between BPH with and without urinary tract stones.

Results: In total, 235 BPH patients were registered, of whom 74 (31.5%) had urinary tract stones. The median age was 64 years old. There was a relationship between age (p=0.030), diabetes mellitus (p=0.043), and the occurrence of urinary tract stones in patients with BPH. The most dominant risk factor was diabetes mellitus (OR=3.000, 95%CI 1.03-8.69).

Conclusions: Age and diabetes mellitus are the risk factors for urinary tract stones in patients with BPH. BPH patients with diabetes mellitus are at a 3-fold risk for urinary tract stones. Diabetes mellitus in BPH patients is an indication to conduct imaging tests.


Benign prostatic hyperplasia, diabetes mellitus, urinary tract stones

Full Text:



Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148–51.

Nagarathnam M, Latheef SAA. Prevalence of lower urinary tract symptoms in patients of benign prostatic hyperplasia attending tertiary care hospital in the State of Andhra Pradesh. J Dr NTR Univ Health Sci. 2017;6(3):154–7.

Thiruchelvam N. Benign prostatic hyperplasia. Surgery (Oxford). 2014;32(6):314–22.

Roehrborn CG. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi LR, Partin AW, Peters C. Campbell-Walsh urology. 11th ed. Philadephia: Elsevier; 2016. p. 3242–88.

Jung JH, Park J, Kim WT, Kim HW, Kim HJ, Hong S, et al. The association of benign prostatic hyperplasia with lower urinary tract stones in adult men: A retrospective multicenter study. Asian J Urol. 2018;5(2):118–21.

Liu Y, Chen Y, Liao B, Luo D, Wang K, Li H, et al. Epidemiology of urolithiasis in Asia. Asian J Urol. 2018;5(4):205–14.

Aggarwal R, Srivastava A, Jain SK, Sud R, Singh R. Renal stones: a clinical review. EMJ Urol. 2017;5(1):98–103.

Tjahjodjati, Soebadi DM, Umbas R, Poernomo BB, Wijanarko S, Mochtar CA, et al. Panduan penatalaksanaan klinis pembesaran prostat jinak (Benign Prostatic Hyperplasia/BPH). 3rd ed. Jakarta: IAUI; 201. p. 1–12.

Lukito AA, Harmeiwaty E, Hustrini NM, editors. Konsensus penatalaksanaan hipertensi 2019. Jakarta: Perhimpunan Dokter Hipertensi Indonesia; 2019. p. 7–8.

World Health Organization Regional Office for the Western Pacific. The Asia-Pasific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000. p. 17.

Besiroglu H, Otunctemur A, Ozbek E. The metabolic syndrome and urolithiasis: a systematic review and meta-analysis. Ren Fail. 2015;37(1):1–6.

Boyd C, Wood K, Whitaker D, Assimos DG. The influence of metabolic syndrome and its components on the development of nephrolithiasis. Asian J Urol. 2018;5(4):215–22.

Pfau A, Knauf F. Update on nephrolithiasis: core curriculum 2016. Am J Kidney Dis. 2016;68(6):973–85.

Trinchieri A, Croppi E, Montanari E. Obesity and urolithiasis: evidence of regional influences. Urolithiasis. 2017;45(3):271–8.

Aydogdu O. Urinary stone disease and obesity: different pathologies sharing common biochemical mechanisms. World J Nephrol. 2012;1(1):12–5.

Lim D-H, Kim M, Hong S, Kim Y-G, Lee C-K, Choi SW, et al. Is the serum uric acid level independently associated with incidental urolithiasis? J Rheum Dis. 2018;25(2):116–21.

Alexander RT, McArthur E, Jandoc R, Welk B, Hayward JS, Jain AK, et al. Antihypertensive medications and the risk of kidney stones in older adults: a retrospective cohort study. Hypertens Res. 2017;40(9):837–42.

Wong Y V, Cook P, Somani BK. The association of metabolic syndrome and urolithiasis. Int J Endocrinol. 2015;2015:1–9.

Abou-Elela A. Epidemiology, pathophysiology, and management of uric acid urolithiasis: a narrative review. J Adv Res. 2017;8(5):513–27.

DOI: https://doi.org/10.15850/amj.v8n2.2257

 This Journal indexed by


Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License


View My Stats